Over the past decade, the use of immune checkpoint inhibitors and antibody–drug conjugates has led to longer survival in patients with metastatic bladder cancer. Platinum-based chemotherapy had been the standard of care for decades. The combination of enfortumab vedotin, an antibody–drug conjugate directed against nectin-4, and pembrolizumab, a programmed death…
The New England Journal of Medicine: Search Results in Hematology/Oncology
